Clinical observation of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease of the lung and kidney deficiency type
|更新时间:2022-08-31
|
Clinical observation of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease of the lung and kidney deficiency type
Shanghai Journal of Traditional Chinese MedicineVol. 49, Issue 5, Pages: 45-47(2015)
作者机构:
1. 上海中医药大学附属龙华医院特需病房,上海,200032
2. 上海中医药大学研究生院,上海,201203
3. 上海市浦东新区浦南医院内科,上海,200125
4. 上海市浦东新区迎博社区卫生服务中心内科,上海,200125
5. 上海市香山中医医院中医内科,上海,200020
作者简介:
基金信息:
DOI:
CLC:
扫 描 看 全 文
CHEN Chen, ZHAO Wen-qing, AN Shi-ying, et al. Clinical observation of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease of the lung and kidney deficiency type. [J]. Shanghai Journal of Traditional Chinese Medicine 49(5):45-47(2015)
DOI:
CHEN Chen, ZHAO Wen-qing, AN Shi-ying, et al. Clinical observation of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease of the lung and kidney deficiency type. [J]. Shanghai Journal of Traditional Chinese Medicine 49(5):45-47(2015)DOI:
Clinical observation of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease of the lung and kidney deficiency type
Objective:To observe the clinical efficacy of “Sansang Huoxue Decoction” on pulmonary hypertension of patients with stable phase of chronic obstructive pulmonary disease (COPD) of the lung and kidney deficiency type Methods:One hundred and twenty-six patients in stable phase of COPD with pulmonary hypertension of the lung and kidney deficiency type were randomized into treatment group and control group, with 63 patients in each group. The control group was treated by routine western therapy. The treatment group was treated by “Sansang Huoxue Decoction” additionally. The treatment course was 3 months. The clinical efficacy, TCM syndrome score, mean pulmonary artery pressure, lung function, 6-minute walking distance and inflammation factors were observed Results:①The total effective rate was 82.54% in the treatment group and 41.27% in the control group, with a difference between the two groups(P,<,0.05). ② There were significant differences in the TCM syndrome score, 6-minute walking distance between before and after treatment of the two groups (P,<,0.05). The treatment group has statistically difference in mean pulmonary artery pressure (P,<,0.05). After treatment, there were significant differences in the TCM syndrome score and 6-minute walking distance between the two groups (P,<,0.05). ③There were significant differences in the levels of FEV,1, RV/TLC, R5 and R20 of the treatment group between before and after treatment (P,<,0.05), and with significant differences in the levels of RV/TLC, R5 and R20 of the control group between before and after treatment (P,<,0.05); After treatment, there were significant differences in the levels of RV/TLC, R5 and R20 between the two groups (P,<,0.05). ④There were significant differences in the levels of IL-6, IL-8 and hs-CRP of the treatment group between before and after treatment (P,<,0.05), and there were significant differences in the levels of IL-6 and hs-CRP of the control group (P,<,0.05). After treatment, there were significant differences in the levels of IL-8 and hs-CRP between the two groups (P,<,0.05) Conclusion:Combined “Sansang Huoxue Decoction” and western routine western therapy is effective to lower the mean pulmonary arterial pressure, improve small airway of lung function and body inflammation, and enhance exercise tolerance in patients with COPD of the lung and kidney deficiency type.